25.04.2018
SHOP APOTHEKE EUROPE N.V. NL0012044747
DGAP-News: Preliminary sales: SHOP APOTHEKE EUROPE achieves an excellent start into the financial year 2018 with a 105 % revenue increase in Q1.
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Preliminary
Results/Development of Sales
Preliminary sales: SHOP APOTHEKE EUROPE achieves an excellent start into the
financial year 2018 with a 105 % revenue increase in Q1.
25.04.2018 / 06:59
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR RELEASE OT DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
Preliminary sales: SHOP APOTHEKE EUROPE achieves an excellent start into the
financial year 2018 with a 105 % revenue increase in Q1.
* Group revenues more than doubled to EUR 131 million in first quarter.
* Growth rate 105% after 58% in the same quarter of the previous year.
* Guidance for the financial year 2018 confirmed.
Venlo, 25 April 2018. SHOP APOTHEKE EUROPE N.V., the leading online pharmacy
in Continental Europe, has achieved a dynamic start into the 2018 financial
year (01.01.-31.12.), thus further expanding its market position in Germany
and Continental Europe. Supported by the integration of Europa Apotheek
which was acquired in November 2017, SHOP APOTHEKE EUROPE again increased
its growth rate and boosted group revenues by 105% to EUR 131 m. Management
Board reaffirms its guidance for revenue growth to EUR 530 m to 560 m (+87%
to +97%) and a positive EBITDA* of EUR 0 to 2 m at Group level.
The integration and consolidation of Europa Apotheek led to a significant
acceleration in growth in the "Germany" segment. In Continental Europe's
largest online pharmacy market and SHOP APOTHEKE EUROPE's core market,
revenues in the first quarter rose by 118% to EUR 103.5 m (EUR 47.5 m in the
previous year).
SHOP APOTHEKE EUROPE also recorded a dynamic growth in the international
markets, including Austria, France, Belgium, the Netherlands, Spain and
Italy. Business volume in the "International" segment was up by EUR 11.1 m
in absolute terms from EUR 16.0 m to EUR 27.1 m. This corresponds to a
growth of more than 69%.
Based on the strong growth in the first quarter, Management Board reaffirms
its guidance for the financial year 2018: The planned increase in group
revenues of 87% to 97% to EUR 530 m to 560 m will particularly be driven by
the growing international business and the consolidation of Europa Apotheek.
Due to further gains in efficiency and economies of scale, the company also
plans to achieve a positive EBITDA* of EUR 0 to 2 m at Group level.
Potential acquisitions are not included in the forecast for the full year.
SHOP APOTHEKE EUROPE intends to maintain its active role in the ongoing
market consolidation. In order to be able to act swiftly and to take
advantage of upcoming target opportunities in a flexible way, the company
successfully placed EUR 75m convertible bonds with institutional investors
on April 12. Net proceeds will primarily be used to finance OTC acquisitions
in the German market to further accelerate the Group's growth in its most
developed core market.
Dr. Ulrich Wandel, CFO of SHOP APOTHEKE EUROPE N.V., adds: "The successful
issuance of convertible bonds by SHOP APOTHEKE EUROPE N.V. confirms the high
confidence of the capital markets in our European growth story".
* before one-off costs
All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE
will publish the complete interim statement for the first quarter of 2018 as
scheduled on 15 May 2018.
ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in
Continental Europe. SHOP APOTHEKE EUROPE already operates online pharmacies
in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In
Germany, the TÜV-certified shop-apotheke.com is the market leading. SHOP
APOTHEKE EUROPE delivers a broad range of more than 100,000 original
products to about 2.8 million active customers quickly and at attractive
prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and
consistent pharmaceutical services.SHOP APOTHEKE EUROPE N.V. has been listed
on the regulated market of the Frankfurt Stock Exchange (Prime Standard)
since 13 October 2016.
MEDIA CONTACTS.
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: [email protected]
Investor Relations:
Dr. Ulrich Wandel
Telephone: +31 77 850 6117
Email: [email protected]
DISCLAIMER.
This publication is an advertisement.
This communication constitutes neither an offer to sell nor a solicitation
to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is
not a securities prospectus. No public offering of any securities of Shop
Apotheke Europe N.V. is being made.
Statements contained herein may constitute "forward-looking statements."
Forward-looking statements are generally identifiable by the use of the
words "may", "will", "should", "plan", "expect", "anticipate", "estimate,"
"believe", "intend", "project", "goal" or "target" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are based on current expectations and involve a
number of known and unknown risks, uncertainties and other factors that
could cause the Group's or its industry's actual results, levels of
activity, performance or achievements to be materially different from any
future results, levels of activity, performance or achievements expressed or
implied by such forward-looking statements. You should not place undue
reliance on forward-looking statements and the Group does not undertake
publicly to update or revise any forward-looking statement that may be made
herein, whether as a result of new information, future events or otherwise.
---------------------------------------------------------------------------
25.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
678675 25.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
SHOP APOTHEKE EUROPE N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:RDC